Suboxone Treatment for Opioid Use Disorder
What Patients Should Know
Table of Contents
What Patients Should Know
Opioid use disorder (OUD) is a chronic, complex medical condition that affects thousands of Ontarians. Effective, evidence-based treatment is available, and Suboxone treatment pharmacy Toronto services play a meaningful role in helping patients access and maintain their therapy. At Cloud Pharmacy, our licensed pharmacists are committed to providing confidential, judgment-free dispensing and support for patients enrolled in opioid agonist therapy (OAT).
What Is Suboxone?
Suboxone is a Health Canada–approved medication that combines two active ingredients: buprenorphine and naloxone. It is available as a sublingual film (dissolved under the tongue) and is one of the most widely used medications for opioid agonist therapy in Canada.
Buprenorphine is a partial opioid agonist. Unlike full opioid agonists, it binds to the brain’s opioid receptors with high affinity but produces a submaximal effect. This pharmacological profile means it can significantly reduce opioid cravings and withdrawal symptoms while having a lower potential for respiratory depression than full agonists — a property sometimes referred to as the “ceiling effect.”
Naloxone is an opioid antagonist included in the formulation specifically to deter misuse by injection. When Suboxone is taken as prescribed (sublingually), the naloxone component is poorly absorbed and has minimal effect. However, if the medication were injected, the naloxone would become active and could precipitate acute opioid withdrawal — a powerful deterrent against diversion and misuse.
Suboxone is distinct from methadone, another first-line OAT medication approved in Canada. Both are effective options, and the choice between them depends on clinical assessment, patient history, and the recommendation of the prescribing clinician. Health Canada and provincial health authorities recognize buprenorphine/naloxone as a safe and evidence-based treatment option for OUD.
How Suboxone Treatment Works
Opioid agonist therapy is not a single event — it is a structured, ongoing medical treatment. Suboxone works by occupying opioid receptors in the brain, which helps to:
- Reduce or eliminate withdrawal symptoms during the transition away from other opioids
- Diminish cravings, making it easier to engage in daily activities and recovery supports
- Block the euphoric effects of other opioids, reducing the reinforcing value of their use
- Stabilize neurological function over time, supporting sustained recovery
Treatment is generally organized into three phases:
- Induction: The patient begins taking Suboxone under medical supervision. Timing is important — induction typically begins when a patient is in mild-to-moderate opioid withdrawal to reduce the risk of precipitated withdrawal. A prescribing physician or nurse practitioner will guide this process.
- Stabilization: The dose is adjusted over days to weeks until the patient is comfortable, cravings are well-managed, and withdrawal symptoms are absent. This phase requires close communication between the patient, prescriber, and pharmacist.
- Maintenance: Once a therapeutic dose is established, the patient continues on a consistent regimen. The duration of maintenance therapy varies by individual and is determined collaboratively between the patient and their care team. Clinical guidelines, including those from the Canadian Research Initiative in Substance Misuse (CRISM), support long-term maintenance as a valid and effective treatment approach for many patients.
It is important to understand that Suboxone, like all medications, carries potential risks and side effects. Common effects during early treatment may include headache, nausea, or constipation. Patients should discuss their complete medication list with their pharmacist and prescriber to avoid interactions, particularly with benzodiazepines, alcohol, and other central nervous system depressants.
Starting Suboxone Treatment in Ontario
In Ontario, Suboxone is a controlled substance under Schedule I of the Controlled Drugs and Substances Act and requires a valid prescription from a licensed prescriber — typically a physician or nurse practitioner with appropriate training or registration to prescribe OAT.
The College of Physicians and Surgeons of Ontario (CPSO) and Health Canada have published guidance on the prescribing of opioid agonist therapy. Ontario has also expanded access through initiatives that allow a broader range of clinicians to prescribe buprenorphine/naloxone, reflecting the urgent need to reduce barriers to treatment for people with OUD.
To begin Suboxone treatment in Ontario, patients generally follow these steps:
- Connect with a healthcare provider — this may be a family physician, an addiction medicine specialist, a community health centre, or a nurse practitioner. Online resources such as BupeNow or provincial OAT navigator services can help individuals find a prescriber.
- Complete a clinical assessment. The prescriber will review the patient’s opioid use history, current health status, and other medications to determine whether Suboxone is appropriate and to calculate a starting dose.
- Obtain a prescription and select a pharmacy. Patients have the right to choose their pharmacy. Selecting a pharmacy that offers consistent hours, knowledgeable staff, and confidential dispensing can significantly improve the treatment experience.
- Begin induction under prescriber guidance and establish a dispensing schedule with the pharmacy.
The Ontario Drug Benefit (ODB) program covers buprenorphine/naloxone for eligible Ontarians, and coverage may also be available through private insurance plans. Patients are encouraged to speak with their pharmacist about coverage options.
The Role of the Pharmacy in Opioid Agonist Therapy
Pharmacies are a critical touchpoint in opioid agonist therapy. The Ontario College of Pharmacists (OCP) and the National Association of Pharmacy Regulatory Authorities (NAPRA) have established standards that guide how pharmacists dispense and support OAT patients in Canada.
Key responsibilities of the dispensing pharmacy include:
- Witnessed ingestion: During early treatment, pharmacists typically observe the patient taking their Suboxone dose in the pharmacy. This practice supports patient safety and is a standard component of OAT dispensing protocols.
- Carries (take-home doses): As a patient progresses in treatment and demonstrates clinical stability, the prescriber may authorize carries — doses the patient takes home without daily witnessed ingestion. The criteria for carries are outlined by OCP standards and the patient’s clinical team.
- Medication counselling: Pharmacists are trained to counsel patients on how to take Suboxone correctly, what to expect during treatment, how to manage minor side effects, and when to contact their prescriber.
- Identifying drug interactions: A pharmacist reviews the patient’s full medication profile to flag potential interactions — a particularly important function for patients managing multiple health conditions.
- Continuity of care: Regular contact with a pharmacist provides a consistent point of connection in the healthcare system, which can be especially valuable for patients who face barriers to frequent physician appointments.
Pharmacists do not prescribe or diagnose — their role is to dispense safely, counsel thoroughly, and collaborate with the broader care team. This coordination between prescribers, pharmacists, and other support services forms the foundation of effective OAT.
Support Services at Cloud Pharmacy
At Cloud Pharmacy in Toronto, we understand that patients enrolled in opioid agonist therapy benefit from a pharmacy environment that is respectful, accessible, and discreet. Our team of licensed pharmacists is trained to support OAT patients with the same professionalism and compassion extended to every patient we serve.
Our services for OAT patients include:
- Confidential dispensing: We prioritize your privacy. All dispensing and counselling conversations are handled with discretion, in accordance with Ontario’s Personal Health Information Protection Act (PHIPA).
- Flexible scheduling: We work with patients and prescribers to accommodate dispensing schedules that fit individual needs, including morning and evening availability where possible.
- Medication review and counselling: Our pharmacists are available to answer questions about your Suboxone regimen, potential interactions with other medications, and what to do if a dose is missed.
- Prescription delivery: For patients who qualify for take-home doses, or who have additional medications as part of their overall care, we offer prescription delivery services across Toronto and the surrounding area.
- Compounding services: In some cases, patients may require customized formulations as part of their broader treatment plan. Our compounding medications service can prepare individualized preparations when prescribed by a clinician.
We believe that access to consistent, high-quality pharmacy care is a fundamental component of successful opioid agonist therapy. Our goal is to reduce barriers and provide a stable, supportive dispensing environment for every patient.
Frequently Asked Questions
Is Suboxone covered by OHIP or the Ontario Drug Benefit program?
Buprenorphine/naloxone (Suboxone) is listed on the Ontario Drug Benefit (ODB) formulary and is available at no cost to eligible Ontarians, including those with a valid Ontario health card who meet ODB eligibility criteria. Patients with private insurance may also have coverage. A Cloud Pharmacy pharmacist can help you determine your coverage options and explain any out-of-pocket costs before you fill your prescription.
Do I need to come to the pharmacy every day to get my Suboxone?
During the early stages of treatment, daily witnessed ingestion at the pharmacy is a standard part of the dispensing protocol, as outlined by the Ontario College of Pharmacists. As treatment progresses and clinical stability is established, your prescriber may authorize carry doses, allowing you to take some or all of your medication at home. The criteria for carries are individualized and determined by your prescriber based on clinical assessment.
What should I do if I miss a dose of Suboxone?
If you miss a dose, contact your prescribing clinician and your pharmacist as soon as possible. Do not double up on doses without guidance from your healthcare provider. Missing doses can increase the risk of withdrawal symptoms and may affect your treatment schedule. Our pharmacists at Cloud Pharmacy are available to advise you and help coordinate with your prescriber if needed.
Can I switch from methadone to Suboxone, or vice versa?
Transitions between OAT medications are possible but must be managed carefully under medical supervision. Switching from methadone to buprenorphine/naloxone, in particular, requires a carefully timed induction to reduce the risk of precipitated withdrawal. Any decision to change your OAT medication should be made in close consultation with your prescribing clinician, who can assess your clinical history and provide appropriate guidance. Your pharmacist can also be a resource in this conversation.
Is it safe to take Suboxone while pregnant?
This is an important question that should be discussed directly with an obstetric provider and an addiction medicine clinician. Health Canada and Canadian clinical guidelines recognize that untreated opioid use disorder during pregnancy carries significant risks, and that opioid agonist therapy — including buprenorphine-based medications — may be recommended in appropriate clinical circumstances. Decisions about OAT during pregnancy are individualized and require careful medical oversight. Cloud Pharmacy’s pharmacists can provide information to support the conversation with your care team, but clinical decisions of this nature are made by your prescribing physician.
Have questions or need help? Contact Cloud Pharmacy in Toronto — our licensed pharmacists are here to assist you.
This article is for informational purposes only and does not constitute medical advice. Please consult your healthcare provider for personalized guidance. Information in this article may become outdated over time. For the most current clinical guidelines and recommendations, please refer to your healthcare provider or the relevant regulatory body.